Biomea Fusion's (BMEA) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA - Free Report) in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the stock.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Biomea Fusion in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Biomea Fusion currently has a consensus rating of "Buy" and an average target price of $29.18.

Biomea Fusion Trading Up 3.6 %

Shares of BMEA traded up $0.10 during mid-day trading on Wednesday, hitting $2.87. The company's stock had a trading volume of 923,761 shares, compared to its average volume of 921,134. The company's 50-day moving average is $3.47 and its 200-day moving average is $6.16. Biomea Fusion has a 52-week low of $2.35 and a 52-week high of $16.29. The firm has a market capitalization of $104.01 million, a price-to-earnings ratio of -0.72 and a beta of -0.26.

Institutional Investors Weigh In On Biomea Fusion

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wexford Capital LP lifted its position in Biomea Fusion by 2.3% during the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company's stock valued at $517,000 after acquiring an additional 3,007 shares during the last quarter. Two Sigma Advisers LP increased its stake in Biomea Fusion by 290.7% during the 4th quarter. Two Sigma Advisers LP now owns 459,500 shares of the company's stock valued at $1,783,000 after purchasing an additional 341,900 shares in the last quarter. Two Sigma Investments LP increased its stake in Biomea Fusion by 104.4% during the 4th quarter. Two Sigma Investments LP now owns 559,930 shares of the company's stock valued at $2,173,000 after purchasing an additional 286,049 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Biomea Fusion during the 4th quarter valued at approximately $766,000. Finally, Graham Capital Management L.P. acquired a new position in Biomea Fusion during the 4th quarter valued at approximately $307,000. Hedge funds and other institutional investors own 96.72% of the company's stock.

Remove Ads

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.